Skip to main content

Advertisement

SpringerLink
Log in

DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen

8.4 Medikamentöse Therapie, 8.5 Evaluation des Therapieerfolgs medikamentöser Maßnahmen

German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms

8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures

  • Leitlinien
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Barkhuizen A et al (2006) Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 33(9):1805–1812

    PubMed  Google Scholar 

  2. Dougados M et al (1989) A double blind crossover placebo controlled trial of ximoprofen in as. J Rheumatol 16(8):1167–1169

    CAS  PubMed  Google Scholar 

  3. Dougados M et al (1994) Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 23(5):243–248

    CAS  PubMed  Google Scholar 

  4. Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 33(2):129–131

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Heijde D van der et al (2005) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52(4):1205–1215

    PubMed  Google Scholar 

  6. Gossec L et al (2005) Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 64(11):1563–1567

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Sieper J et al (2008) Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 67(3):323–329

    CAS  PubMed  Google Scholar 

  8. Escalas C, Trijau S, Dougados M (2010) Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford) 49(7):1317–1325

  9. Zochling J et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis – a population-based survey. Clin Rheumatol 25(6):794–800

    PubMed  Google Scholar 

  10. Wanders A et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52(6):1756–1765

    CAS  PubMed  Google Scholar 

  11. Kroon F et al (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623–1629

    CAS  PubMed  Google Scholar 

  12. Poddubnyy D et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71(10):1616–1622

    CAS  PubMed  Google Scholar 

  13. Jarrett SJ et al (2009) MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 68(9):1466–1469

    CAS  PubMed  Google Scholar 

  14. Benhamou M, Gossec L, Dougados M (2010) Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs‘ treatment effect on C-reactive protein. Rheumatology (Oxford) 49(3):536–541

  15. Peloso PM et al (2011) Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. BMC Musculoskelet Disord 12:165

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Heijde D van der et al (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6):905–908

    PubMed  Google Scholar 

  17. Cannon CP et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368(9549):1771–1781

    CAS  PubMed  Google Scholar 

  18. Farkouh ME et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364(9435):675–684

    CAS  PubMed  Google Scholar 

  19. Song IH et al (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58(4):929–938

    CAS  PubMed  Google Scholar 

  20. Bolten W (2009) Nichtsteroidale Antirheumatika, aktualisierte Empfehlungen zur Verordnung. Deutsche Gesellschaft für Rheumatologie

  21. Burmester G et al (2011) The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 70(5):818–822

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Ärzteschaft, A.d.d. (2008) Empfehlungen zur Therapie von degenerativen Gelenkerkrankungen, Bd. 35, Sonderheft 1. A.d.d. Ärzteschaft

  23. Basavaraj KH et al (2010) The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 49(12):1351–1361

    CAS  PubMed  Google Scholar 

  24. Braun J et al (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896–904

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Braun J et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505

    CAS  PubMed  Google Scholar 

  26. Zochling J et al (2006) Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65(4):423–432

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Heijde D van der et al (2008) Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67(9):1218–1221

    PubMed  PubMed Central  Google Scholar 

  28. Dougados M et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799–804

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Haibel H et al (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58(7):1981–1991

    CAS  PubMed  Google Scholar 

  30. Song IH et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70(4):590–596

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Barkham N et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946–954

    CAS  PubMed  Google Scholar 

  32. Sieper J et al (2012) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis

  33. Heijde D van der et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146

    PubMed  Google Scholar 

  34. Heijde D van der et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922–929

    PubMed  PubMed Central  Google Scholar 

  35. Heijde DM van der et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124

    PubMed  PubMed Central  Google Scholar 

  36. Davis JC Jr et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236

    CAS  PubMed  Google Scholar 

  37. Davis JC et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64(11):1557–1562

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Davis JC Jr et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67(3):346–352

    CAS  PubMed  Google Scholar 

  39. Calin A et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Dijkmans B et al (2009) Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36(6):1256–1264

    CAS  PubMed  Google Scholar 

  41. Martin-Mola E et al (2010) Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(2):238–245

    CAS  PubMed  Google Scholar 

  42. Heijde D van der et al (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572–1577

    PubMed  PubMed Central  Google Scholar 

  43. Dougados M et al (2010) A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 69(8):1430–1435

    CAS  PubMed  Google Scholar 

  44. Navarro-Sarabia F et al (2011) High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford) 50(10):1828–1837

  45. Braun J et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543–1551

    CAS  PubMed  Google Scholar 

  46. Inman RD et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412

    CAS  PubMed  Google Scholar 

  47. Braun J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193

    CAS  PubMed  Google Scholar 

  48. Braun J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64(2):229–234

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Braun J et al (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44(5):670–676

  50. Braun J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345

    CAS  PubMed  Google Scholar 

  51. Baraliakos X et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years – early clinical response predicts long-term outcome. Rheumatology (Oxford) 50(9):1690–1699

  52. Heijde D van der et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591

    PubMed  Google Scholar 

  53. Heldmann F et al (2011) The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 29(4):672–680

    CAS  PubMed  Google Scholar 

  54. Revicki DA et al (2008) Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 35(7):1346–1353

    CAS  PubMed  Google Scholar 

  55. Kristensen LE et al (2010) Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 62(10):1362–1369

    Google Scholar 

  56. Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226–229

    CAS  PubMed  Google Scholar 

  57. Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451

    CAS  PubMed  Google Scholar 

  58. Braun J et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639–647

    CAS  PubMed  Google Scholar 

  59. Cohen JD et al (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 34(2):380–385

    CAS  PubMed  Google Scholar 

  60. Vries MK de et al (2009) Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61(11):1484–1490

    PubMed  Google Scholar 

  61. Braun J et al (2009) Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 61(8):1032–1036

    CAS  PubMed  Google Scholar 

  62. Gonnet-Gracia C et al (2008) Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 26(3):401–407

    CAS  PubMed  Google Scholar 

  63. Baraliakos X et al (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216–1223

    CAS  PubMed  Google Scholar 

  64. Braun J et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54(5):1646–1652

    CAS  PubMed  Google Scholar 

  65. Maksymowych WP et al (2010) Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 37(8):1728–1734

    CAS  PubMed  Google Scholar 

  66. Heijde D van der et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331

    PubMed  Google Scholar 

  67. Baraliakos X et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46(9):1450–1453

  68. Visvanathan S et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68(2):175–182

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Davis JC Jr et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57(6):1050–1057

    PubMed  Google Scholar 

  70. Braun J et al (2007) Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 46(6):999–1004

  71. Boonen A et al (2008) Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 35(4):662–667

    CAS  PubMed  Google Scholar 

  72. Kimel M et al (2011) Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Clin Exp Rheumatol 29(4):624–632

    CAS  PubMed  Google Scholar 

  73. Verstappen SM et al (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(5):823–826

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Villiger PM et al (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69(10):1842–1844

    CAS  PubMed  Google Scholar 

  75. Heijde D van der et al (2006) Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 55(4):569–574

    PubMed  Google Scholar 

  76. Barkham N et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928

    CAS  PubMed  Google Scholar 

  77. Keat AC et al (2008) Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology (Oxford) 47(4):481–483

  78. Kristensen LE et al (2011) Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology (Oxford)

  79. Maksymowych WP et al (2010) Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 37(2):385–392

    PubMed  Google Scholar 

  80. Braun J et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62(9):817–824

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Braun J et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65(3):316–320

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Kiltz U, Sieper J, Braun J (2013) ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis: evaluation of the 2010 update in the German-speaking area. Z Rheumatol 72(1):81–88

    CAS  PubMed  Google Scholar 

  83. Heijde D van der et al (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24(11):2225–2229

    PubMed  Google Scholar 

  84. Heiberg MS et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59(2):234–240

    CAS  PubMed  Google Scholar 

  85. Arends S et al (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 13(3):R94

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Vastesaeger N et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70(6):973–981

    PubMed  PubMed Central  Google Scholar 

  87. Glintborg B et al (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years‘ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 69(11):2002–2008

    CAS  PubMed  Google Scholar 

  88. Lord PA et al (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 49(3):563–570

  89. Sieper J et al (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71(5):700–706

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Breban M et al (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58(1):88–97

    CAS  PubMed  Google Scholar 

  91. Marzo-Ortega H et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568–1575

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Li EK et al (2008) Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 47(9):1358–1363

  93. Perez-Guijo VC et al (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254–258

    CAS  PubMed  Google Scholar 

  94. Giardina AR et al (2010) A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int 30(11):1437–1440

    PubMed  Google Scholar 

  95. Braun J et al (2011) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis

  96. Braun J et al (2011) Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis

  97. Baraliakos X et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Inman RD, Maksymowych WP (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37(6):1203–1210

    PubMed  Google Scholar 

  99. Krzysiek R et al (2009) Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 61(5):569–576

    CAS  PubMed  Google Scholar 

  100. Arends S et al (2010) The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668

    CAS  PubMed  Google Scholar 

  101. Vries MK de et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252–1254

    PubMed  PubMed Central  Google Scholar 

  102. Bartelds GM et al (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 69(5):817–821

    CAS  PubMed  Google Scholar 

  103. Vries MK de et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68(4):531–535

    PubMed  Google Scholar 

  104. Lie E et al (2011) Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 70(1):157–163

    CAS  PubMed  Google Scholar 

  105. Rudwaleit M et al (2010) Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 12(3):R117

    PubMed  PubMed Central  Google Scholar 

  106. Diel R et al (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 63(6):329–334

    CAS  PubMed  Google Scholar 

  107. Fouque-Aubert A et al (2010) Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69(10):1756–1761

    CAS  PubMed  Google Scholar 

  108. Mariette X et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895–1904

    PubMed  Google Scholar 

  109. Pham T et al (2011) TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 78(Suppl 1):15–185

    PubMed  Google Scholar 

  110. Song IH et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62(5):1290–1297

    CAS  PubMed  Google Scholar 

  111. Song IH et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 70(6):1108–1110

    CAS  PubMed  Google Scholar 

  112. Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2:CD004800

    PubMed  Google Scholar 

  113. Genc H et al (2007) The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. Clin Rheumatol 26(7):1104–1110

    PubMed  Google Scholar 

  114. Braun J et al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Benitez-Del-Castillo JM et al (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 14 (Pt 3A):340–343

  116. Hoffmann JC et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146

    CAS  PubMed  Google Scholar 

  117. Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD004524

    PubMed  Google Scholar 

  118. Maksymowych WP et al (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46(3):766–773

    CAS  PubMed  Google Scholar 

  119. Haibel H et al (2003) Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) 42(8):1018–1020

  120. Cairns AP et al (2005) An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 64(2):338–339

    CAS  PubMed  PubMed Central  Google Scholar 

  121. Malaviya AN et al (2007) A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 55:193–197

    CAS  PubMed  Google Scholar 

  122. Santra G et al (2010) Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med J 51(11):883–887

    CAS  PubMed  Google Scholar 

  123. Chatfield SM et al (2009) Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 28(2):213–217

    PubMed  Google Scholar 

  124. Brophy S et al (2008) Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy. BMC Musculoskelet Disord 9:4

    PubMed  PubMed Central  Google Scholar 

  125. Jenks K et al (2010) Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol 37(10):2118–2125

    PubMed  Google Scholar 

  126. Heijde D van der et al (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 11(4):R127

    PubMed  PubMed Central  Google Scholar 

  127. Han C et al (2007) The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 9(5):R103

    PubMed  PubMed Central  Google Scholar 

  128. Visvanathan S et al (2008) Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 67(4):511–517

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. U. Kiltz, J. Sieper, H. Kellner, D. Krause, M. Rudwaleit, J.-F. Chenot, A. Stallmach, S. Jaresch und J. Braun geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren. This article is part of a supplement sponsored by AbbVie, Pfizer und UCB.

Author information

Authors and Affiliations

  1. Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Deutschland

    U. Kiltz, J. Sieper, H. Kellner, D. Krause, M. Rudwaleit & J. Braun

  2. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), Frankfurt a.M., Deutschland

    J.-F. Chenot

  3. Deutsche Gesellschaft für Innere Medizin (DGIM), Wiesbaden, Deutschland

    A. Stallmach & S. Jaresch

Authors
  1. U. Kiltz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Sieper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Kellner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Rudwaleit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J.-F. Chenot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Stallmach
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Jaresch
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Kiltz.

Additional information

Die Empfehlungen finden sich in Tab. 1 und 3–5.

Systematische Literatursuche: Evidenztabellen Tab. 6–13.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kiltz, U., Sieper, J., Kellner, H. et al. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen. Z. Rheumatol. 73 (Suppl 2), 78–96 (2014). https://doi.org/10.1007/s00393-014-1443-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-014-1443-7

Search

Navigation